FRAMINGHAM, Mass., Nov. 8, 2021 /PRNewswire/ — BERG, the clinical stage biotech that employs patient biology and artificial intelligence (AI) to research diseases and develop innovative treatments, today announced their participation at the Society for Neuroscience (SfN) Annual Meeting from November 8-11, 2021. At the event, the company will highlight their ongoing research into interventions…

FRAMINGHAM, Mass., Sept. 16, 2021 /PRNewswire/ — BERG, a clinical-stage biotech that employs patient biology and artificial intelligence (AI) to research diseases and develop innovative treatments, today announced its participation at the European Society for Medical Oncology (ESMO) 2021 Congress, from September 16-21, 2021. At the event, the company will unveil its most recent medical…

FRAMINGHAM, Mass., July 29, 2021 /PRNewswire/ — BERG, a clinical-stage biotech that employs patient biology and artificial intelligence (AI) to research diseases and develop innovative treatments and diagnostics, today announced the publication of a new study, entitled “Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia” in Scientific Reports….

FRAMINGHAM, Mass., July 14, 2021 /PRNewswire/ — BERG, a clinical-stage biotech that employs patient biology and artificial intelligence (AI) to research diseases and develop innovative treatments, will present two poster presentations at the Society for Neuro-Oncology: Basic and Translational Omics of Brain Tumors and Their Microenvironment Conference, on July 15th and 16th, 2021. The first…

FRAMINGHAM, Mass., June 2, 2021 /PRNewswire/ — BERG, a clinical-stage biotech that employs patient biology and artificial intelligence (AI) to research diseases and develop innovative treatments, today announced results from a recently completed Phase 1 study of its investigational drug, BPM 31510 (novel ubidecarenone formulation) in recurrent glioblastoma multiforme (GBM). The study will be presented…